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Abstract 
Academic centres, hospitals and small companies, as typical development settings for UK 
regenerative medicine assets, are significant contributors to the development of autologous 
cell-based therapies. Often lacking the appropriate funding, quality assurance heritage or 
specialist regulatory expertise, qualifying aseptic cell processing facilities for Good 
Manufacturing Practice (GMP) compliance is a significant challenge. The qualification of a 
new Cell Therapy Manufacturing Facility (CTMF) with automated processing capability, the 
first of its kind in a UK academic setting, provides a unique demonstrator for the qualification 
of small-scale, automated facilities for GMP compliant manufacture of autologous cell-based 
products in these settings. This paper shares our experiences in qualifying the CTMF, 
focussing on our approach to streamlining the qualification effort, the challenges, project 
delays and inefficiencies we encountered and the subsequent lessons learned. 
Key Words: 
ATMP, autologous, automation, cell therapy, GMP, manufacturing, qualification, regulation, 
validation. 
Page 2 of 34 
Introduction 
In Europe, the major stakeholders developing cell-based therapy products are academic 
centres, hospitals, charitable organisations and small companies. Academic and clinical 
centres with Good Manufacturing Practice (GMP) compliant facilities are now significant 
contributors to the development and manufacture of investigational autologous cell-based 
therapies [1-5]. In the UK, a small number of GMP manufacturing facilities have been 
established within major academic institutions and teaching hospitals. Many of these are 
licensed by the Medicines and Healthcare product Regulatory Agency (MHRA) to 
manufacture cellular therapies for use in clinical trials or to make small-scale batches of 
material for prescribing on a named patient basis under the UK ‘Specials’ licence [6,7]. 
Others are in the design, build or validation phase prior to regulatory accreditation. 
Currently undergoing validation, the new purpose built Cell Therapy Manufacturing Facility 
(CTMF), housed within the Centre for Biological Engineering (CBE) at Loughborough 
University, UK is an example of one such facility. Funded by Loughborough University, with 
the support of the Engineering and Physical Sciences Research Council (EPSRC) and the 
former East Midlands Development Agency (emda), the design, construction and 
commissioning of the CTMF was completed in conjunction with a specialist cleanroom 
engineering company in February 2009. Designed for multi-patient autologous product 
manufacturing, the CTMF, with the ‘GMP specified’ CompacT Cellbase automated cell 
culture system (TAP Biosystems) at its core, provides cleanroom facilities to Grade B 
standard, with separate production areas and equipment for both manual and automated cell 
culture in Grade A environments [8] (Figure 1 & 2).  
Under the European directives regulating the manufacture of Advanced Therapy Medicinal 
Products (ATMPs) in which the principles of GMP apply [8,9], a programme of work to 
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qualify the facility and the CompacT Select automated cell culture system began in March 
2010. The objectives were to establish and provide documented evidence that the premises, 
equipment, utilities and operating systems were designed in accordance with the requirements 
of GMP (Design Qualification; DQ) and are built, installed and operate in compliance with 
their design specification (Installation Qualification (IQ)/Operational Qualification (OQ)).  
At the time, the ATMP regulations were evolving and their interpretation also uncertain [10]. 
Only a small number of academic GMP qualified facilities were operational in the UK with 
none having automated cell processing capability. Changes in the regulatory landscape have 
continued, evidenced by recent revisions to the European guidelines for GMP and process 
validation [11-13]. Moreover, other potentially far reaching developments in the existing 
ATMP regulation, reported recently by the European Commission, now envision a more 
favourable environment for ATMP developers in academic settings and significantly, 
recognise the specific characteristics of autologous products [14,15]. Against this backdrop, 
the CTMF qualification project provides an opportune and unparalleled demonstrator for the 
qualification of small-scale facilities for the GMP compliant, automated production of 
autologous cell-based products in academic, hospital or small company settings. 
This paper shares our experiences as we progressed along the facility qualification pathway. 
It focuses on our approach to streamlining the qualification effort, the challenges, project 
delays and inefficiencies we encountered and the subsequent lessons learned. The paper is 
formatted into four main phases of the qualification programme that breakdown into a 
number of lessons learned within each phase, highlighting those specifically related to 
qualification of the CompacT Cellbase. 
< Insert Figure 1 here> 
<Insert Figure 2 here> 
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Project Initiation 
Develop a clear business strategy and secure long-term Institutional buy in 
The availability of the skills and infrastructure for the CTMF project grew out of the industry 
supported academic research carried out at Loughborough University during the EPSRC-
funded remedi project [16]. At the time, the regenerative medicine industry in the UK was 
still in its infancy as a commercial entity. Academic resources beyond the initial investment 
in the infrastructure were unpredictable and to an extent remain so. Establishing a clear 
business strategy and long term project plan from the outset was therefore unrealistic. In fact, 
academic uncertainties deferred the formation of a formal validation team until a year after 
the physical completion of the facility. The combined effect was to preclude any advantages 
to be gained from fully integrating the validation requirements into the facility design 
specification and engineering phases of the project at inception. Embodying the economic 
realities of academic and hospital settings this effectively defined the following progressive 
and integrated approaches to both facility qualification and business strategy development 
throughout the project. 
Structure and maintain continuity of the project team  
The critical first step in any qualification project is the formation of a project team that has 
the appropriate experience, knowledge and expertise in the relevant specialised fields such as 
automation, Quality Assurance (QA) and regulatory compliance. These skill sets are often 
rare in academic settings and may need to be drawn, at least in part, from consulting or 
engineering firms or by leveraging existing strengths in other academic or clinical centres 
[5,17]. We for example augmented the project team with external QA expertise, but 
otherwise were able to call on the relevant core competencies from in-house expertise in 
automated cell culture and regulated industry experience in GMP manufacturing [18].  
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These individuals will form the core team or decision making Validation Steering Committee 
(VSC) having intersecting roles at both the management and implementation levels. At the 
management level, the committee’s remit is to oversee the qualification programme and 
coordinate the critical interfaces with the UK regulator (MHRA), the primary collaborators 
(i.e. TAP Biosystems) and institutional and funding stakeholders. At the implementation level, 
a small operational and technically qualified sub-team of the committee needs to be 
constituted and empowered with full decision making authority to plan, prioritise, coordinate 
and execute the facility and equipment qualification activities. Whatever the team 
organisation, it is important to establish individual roles, functions, interdependencies and 
levels of authority at the outset. In academic settings, this helps avoid conflicts with 
commitments that team members may have to other academic activities as the project 
progresses and also situations where personnel move to other research projects before the 
completion of the programme. 
Regular meetings of the VSC ensure continued open communication, planning and 
coordination between team members throughout the duration of the project. Their scheduling 
and agenda is typically compelled by critical project milestones. Adding fixed business and 
regulatory update items to the core agenda makes sure that active business development 
regulatory/industry standards intelligence activities are captured. This assures that business, 
regulatory and operational requirements relevant to the phase of the qualification programme 
are aligned and best practice employed going forward. Likewise, the structure of these 
meetings is important. Our experience shows that a risk and science based approach to 
cohesive decision making and consequent action-led problem resolution is essential to 
ensuring timely and cost-effective project completion. Detailed minutes of each meeting 
provide an informal incremental change record that can be used to simplify reporting to 
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stakeholders. Parenthetically, they also provide a robust validation project history on which 
much of this paper is based. 
Involve a Quality Assurance (QA) function from the start  
Augmenting the core VSC and sub-team with a QA function at the outset widens the 
knowledge, expertise and oversight in areas of GMP, regulatory compliance and industry 
trends. This ensures a clear understanding of the qualification scope and that quality practices 
and procedures are incorporated into the project from the start. 
Map the process of facility qualification 
Usually, the outcomes of a facility qualification project impact several key stakeholders and 
involve activities requiring input from multiple suppliers, contractors or service providers. 
Basic quality management tools such as the suppliers-inputs-process-outputs-customers 
(SIPOC) diagram can be usefully applied to build a high level mutual understanding of the 
project scope and workflow and agree its boundaries. In identifying the feedback and feed-
forward loops between the expectations of the customers (stakeholders), suppliers and the 
critical components of the qualification programme, it allows the project team to construct the 
logical sequence and staging of all the key activities and deliverables. For example, the 
execution of the environmental monitoring protocol by the validation team (P), is triggered 
by the delivery of specified supplies of swabs, settle and contact plates (I) from the supplier 
(S). Samples of airborne and surface viable particles collected during execution of the process 
are packaged (O) for transport to an external vendor for incubation and microbiological 
assessment (C). The sub-processes or activities that make up the environmental monitoring 
protocol specify and convert the inputs into the outputs.  
If the principle of ‘as simple as you can, complex as you must’ is applied this approach can 
help maximise the efficiency of limited internal resource in terms of the level of effort in both 
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performance and documentation of activities. Equally, it helps resolve external resource 
requirements, in terms of minimising the time consumed in securing materials, supplies and 
services necessary to perform activities. It can also assist the project team in predicting 
disruptions so that project risks are recognised early and mitigation efforts can be initiated in 
time. 
Project Planning: Plan the work, challenge it and plan it again 
Adopt a modular validation strategy 
In academic settings, interventional funder timelines centred on capital expenditure can result 
in a time lag between the completion of the facility construction or upgrade and the formation 
of the validation team. This can prevent an orderly turnover of the facility to the validation 
team. Under these circumstances, a modular validation strategy, based for example on the 
ISPE’s Baseline™ Guide to Commissioning and Qualification [19], can be utilised to address 
these shortcomings. As part of the modular validation platform, building a primary document 
base, although not mandatory from a regulatory perspective, provides a means of defining the 
facility, equipment and utilities, together with the manufacturing processes capable of being 
carried out in the facility.  
The qualification activity is derived from these supporting documents, the components of 
which are shown in the top panel of Figure 3. On one level, they provide the foundation and 
supporting evidence to confirm the physical completion of the facility, while also providing 
an entry point and reference to the facility design specification and for facilitating a 
structured design review of the facility. On another level, they allow the engineering 
specifications on which the IQ/OQ is usually based to be related to the process requirements 
(documented in production and process rationales/maps) and the risks critical to product 
quality and safety. Under the modular approach, these rationales drive the qualification effort 
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and provide clarity on what does and does not need to be qualified. When fully integrated 
with a Quality Management System (QMS), a modular approach reduces the complexity 
associated with some traditional top heavy validation approaches. It eliminates unnecessary 
qualification effort and provides a more concise Master Validation Plan (MVP) that is easier 
to understand and implement.  
<Insert Figure 3 here> 
Complete a regulatory requirements analysis 
A formal comprehensive review and analysis of the European regulatory framework for the 
manufacture of ATMPs under GMP is essential [8-10]. It confirms aspects of the facility, 
equipment, utilities and practices involved in the manufacturing process that are critical to 
product quality and safety. Identifying gaps or areas where clarification of the regulatory 
intent and compliance expectation is required, particularly when dealing with novel 
automated systems or settings, provides the impetus and scope for early dialogue with the 
MHRA. In defining the qualification scope and methodology, the analysis allows the project 
team to begin to build the facility MVP and identify the components of the QMS required for 
GMP compliance (Table 1). 
Implement a document management system from the start 
Establishing an electronic, controlled access document management system is an integral part 
of the early planning process and a three-phase construction of the QMS. Phase one focusses 
on the control system requirements. The target of this phase is to establish the primary 
validation policy and procedures, training and change control documentation and to 
implement the supporting document management system. This provides an early workable 
system for change management. Likewise it lays the foundation for determining critical 
timings for the preparation and delivery of the documentation or data required for the 
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operational (Phase two) and management system (Phase three) requirements and for 
qualification activities to progress.  
Establish early consultation with the MHRA and an interface with Institutional 
stakeholders  
Known to be a critical issue in academic and hospital settings, strengthening the interface 
between the site/building operational management systems and the facility with respect to 
security, maintenance and control of critical HVAC (heating, ventilation and air conditioning) 
systems and their air handling units (AHUs) is a priority. This implies that building a reliable 
relationship with the Institutional Facility Management function is vital. Our experience 
shows that this can require a protracted phase of cross-learning at multiple organisational and 
operational levels. It needs to be an integral part of the planning process from inception of the 
project. An early judgement is needed on the level of the site planned preventative 
maintenance (PPM) required and the feasibility of its delivery under existing institutional 
facility management arrangements.  
A recent European survey of academic facilities involved in the development and production 
of ATMPs has indicated that regulatory advice is essential for successful conversion to GMP 
and clinical trial [5]. Similarly, with a novel automated processing system on the one hand 
and regulatory uncertainty on the other, early consultations that the CTMF validation team 
(with the TAP Biosystems design team) had with the MHRA in the project initiation phase 
were critical. By confirming GMP compliance expectations and identifying specific areas 
expected to be subjected to regulatory scrutiny, this helped define the scope of the facility 
qualification effort and was crucial to understanding how automation fits with the GMP 
production of autologous cell-based therapies (Table 1). 
Designed to automate the maintenance and expansion of cells in T-flasks from up to 90 
individual patients in parallel, specific questions were raised about the potential for cross-
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contamination within the CompacT Cellbase processing area; a critical area for all autologous 
processing. Addressing these concerns presented significant scientific and practical 
challenges. The solution was to develop a novel challenge test that could be applied 
specifically to a risk based evaluation of potential cross-contamination pathways within a 
controlled environment GMP setting i.e. that does not in itself create the potential for 
contamination of the environment in which it is used [see Box 1 for experimental details]. 
The utility of this challenge test turned out to be a decisive component of the CompacT 
Cellbase design qualification, obviating the need for major design changes.  
Box 1: CompacT Cellbase Challenge Testing: A novel simulation test system for evaluating 
cross-contamination within GMP controlled processing environments   
Supported by a detailed Failure Modes Effects Analysis (FMEA) of the system, challenge 
experiments were designed to evaluate CompacT Cellbase processing areas and risks associated with 
potential for cross-contamination, aerosol creation and micro-droplet formation. We developed a 
novel challenge test using Glo GermTM as a means of detecting cross-contamination, applicable to 
testing an automated cell culture platform within a GMP regulated environment. Glo GermTM is a 
commercially available hygiene product used for teaching aseptic techniques (www.glogerm.com). It 
comprises 5µm melamine copolymer resin beads that fluoresce under Ultra Violet light illumination 
and has been used previously in novel cytometry applications to measure aerosol containment in high 
velocity cell sorters when sorting potentially biohazardous samples [20,21]. Advantages of using Glo 
GermTM are that it is non-biohazardous, inexpensive, requires no specialist microbiological knowledge 
or handling of bacteria, has minimal preparation time (<30min) and ancillary reagent requirements, 
requires no incubation and provides potentially quantitative and immediately available results [20]. 
All standard system components used in CompacT Cellbase cell processing (pipetting, pouring, 
shaking, swirling, pooling, capping, decapping etc.) were challenged separately using a full system 
usage protocol. Glo GermTM density was determined from a stock solution of Glo GermTM (1g in 
100mL ethanol) by filtering triplicate samples (25mL) of serially diluted Glo GermTM solution (10-8 
dilution, 0.22µm filter) and detecting the number of particles retained on the filter by microscopy. The 
detectable particle density from 1g of Glo GermTM powder in 100mL ethanol was 8×109 particles 
(n=3, µ±σ = 20.1±3.8 particles / 25mL diluted solution. Qualitative assessment was performed before 
and after each challenge run by draping a black-out cloth to cut-out light to the CompacT Cellbase 
processing cabinet and using a UV light the critical processing areas were visually inspected for the 
presence / absence of Glo GermTM particles. Quantitative assessment was performed on all flasks by 
filtering contents through a 0.22µm filter and microscopic assessment of filters for counts of Glo 
GermTM particles. No visible signs of Glo GermTM particles were detected inside the robot cabinet or 
on any of the filter discs.   
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Installation and Operational Qualification Readiness 
Employ an enhanced design review 
In academic or hospital settings, facilities are often transitioning from non-GMP facilities or 
facilities accredited as tissue establishments. Limited capital and manpower resources can 
lead to delays in the turnover of new or renovated facilities to the validation team. These 
situations, especially where regulatory compliance expectations are in a state of flux, place 
greater emphasis on the design qualification and design review of the facility.  
The start of this activity calls for a ‘shakedown’ phase to ensure the design and build of the 
facility reflects its intended use. Involving a documentation gap analysis and a physical 
walkthrough and inspection of the facility build by the validation team, this phase targets the 
identification of minor design errors or deficiencies and areas of non-compliance requiring 
remedial work or implementation of procedural controls. At the same time it confirms where 
design elements are still to be installed or commissioned in the facility. This permits detailed 
comparisons of the functional design and physical arrangement of the facility with the User 
Requirement Specification (URS), GMP and Health & Safety requirements to be made in a 
formal Design Qualification (DQ) protocol (DQ, while not a regulatory requirement, refers 
to the documented verification that the design of the facilities, systems and equipment is 
suitable for the intended purpose). The DQ provides the platform for a rigorous structured 
design review by the VSC. Under a change control process, the resulting remedial plan 
enables the validation deliverables and mitigating actions required to address compliance and 
quality gaps to be prioritised prior to the execution of IQ (pre-IQ) or OQ (pre-OQ). This 
avoids further modifications to the facility or equipment later in the qualification phase which 
might otherwise evoke numerous deviations and change controls resulting in delays and 
increased expenditure. 
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Effect a system impact assessment 
Aligned with the ISPE guidance [19], a system impact assessment of the key design elements 
identified during the DQ phase can be used to streamline the qualification programme. If 
supported by technological risk assessments rather than just generic criteria, critical aspects 
as they relate to product quality and safety, can be used to better classify equipment/systems 
as critical (and/or having direct impact) or non-critical (and/or indirect impact). Decisions 
relating to the extent of qualification then provide the opportunity to finalise the MVP and 
determine the level of resource and effort required to execute the plan.   
Establish facility operational status levels 
Imposing strict cleaning and facility access regimes do little to promote adherence to cleaning 
protocols and consistency of results. Rather, the facility maintenance effort and cost can be 
rationalised by removing non-value added practices during the qualification programme. In 
the CTMF for example, this was achieved by establishing four facility operational status 
levels at the start of the project (Figure 4). These operational levels were constituted to 
manage both the risk and the economies of scope for CTMF operations, primarily in terms of 
the degree and frequency of cleaning, the level of dress code/gowning demanded for facility 
entry and the rate of consumption of energy, materials and consumables e.g. CO2 gases for 
incubators, liquid nitrogen for cryostores etc.  
<Insert Figure 4 here> 
Establish a facility contamination control plan 
Central to GMP, the risk-based contamination control plan lays the foundation for 
maintaining the facility in a state of control as it transitions between operational levels during 
the qualification programme. Risk identification needs to follow a holistic approach, 
screening the whole facility environment for factors and risk nodes influencing the outcomes 
of automated aseptic processing and the levels of contamination (Figure 5). The target of this 
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step is to identify all potential threats and relevant vulnerabilities within this environment so 
that an assessment of the contamination and cross-contamination risks can be made e.g. using 
risk management and assessment tools such as cause and effect diagrams, FMEA etc. The 
facility contamination control plan makes use of this data to identify the sources of 
contamination, routes of transfer and mechanisms of control or risk mitigation specific to 
each of the operational levels. The plan identifies the control mechanisms necessary to 
address the potential risks of contamination. Whether by facility design and qualification, 
procedural control or the enactment of cleaning/disinfection, dress code or training regimes, 
these risk control mechanisms need to become critical elements of the IQ/OQ protocols.  
Streamline the amount of paperwork 
The paperwork and administrative burden associated with GMP is a significant hurdle for 
small academic manufacturers [5]. Documentation practices that do not add value to how 
documents are created and controlled lead to misapplication of the project team’s time to 
areas that have little impact on the ability of the system to meet GMP requirements. Several 
approaches can be adopted to streamline the amount of qualification paperwork. Our 
experience shows that in combination the following approaches serve to improve document 
preparation, review and approval turnaround times and can be effective in minimising 
deviations and time-consuming explanations of errors that can otherwise lengthen and make 
qualification efforts less convincing when audited. These include: the use of qualification 
protocols designed and structured to capture outstanding actions from previous qualification 
activities, which obviate the need for elaborate deviation systems; the establishment of 
document review systems with clear expectations of the value added by the reviewer (e.g. 
technical, regulatory, scientific or editorial) prior to submission; and the creation of 
functional specification documents to support OQ protocol development for each item of 
installed equipment. Furthermore an overarching review system is needed to ensure an 
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ongoing evaluation of areas for improvement by capturing explicit knowledge and experience 
gained from document implementation and execution. 
Perform activities in the right sequence 
Once a compliant facility design has been finalised following the design review, a step-wise 
approach to the qualification phase is needed to maximise the efficiency of internal resources 
and resolve external resource requirements and logistics. This is necessary to verify site 
acceptance testing (SAT) readiness for selected systems, ensure efficient transition between 
IQ and OQ and minimise delays to execution. It can be achieved by a sequenced IQ of each 
room in the facility using structured room IQ protocols. As the final major system audit of the 
facility prior to OQ, this is the critical step by which the qualification, maintenance, 
calibration, training and supply chain activities can be prioritised, such that they and 
associated second level tasks are performed in the right sequence prior to OQ. 
Maximise facility control and operating efficiencies before OQ of critical or direct 
impact equipment 
The implementation of a facility environmental monitoring programme is necessary to 
heighten the level of oversight and control of the facility, utilities and critical equipment 
before starting the OQ. This should be guided by the relevant International Standards (e.g. 
ISO14644-1). Automated Facility Management Systems (FMS) offer advantages over manual 
systems in that they allow regular surveillance of continuous, real-time data from multiple 
located sensors. By measuring trends in non-viable particles and pressure differentials for 
example, this provides a routine diagnostic assessment of facility infrastructure (Figure 1). It 
gives the validation team early warnings of operational inefficiencies or contamination 
problems such that the relevant risk can be recognised early and mitigation actions initiated 
before OQ activities can be disrupted or compromised (Table 1). 
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A parallel activity is to establish baseline airborne and surface viable particle levels under 
static conditions in the unmanned ‘at rest’ state. At this stage, rather than setting high targets 
for acceptable levels of ‘viable contamination’ or bioburden, it is better to adopt a pathway 
approach to establish ‘reference points’ before and after periods of major activity. This is 
sufficient to provide a measure of the state of facility control and allows the effectiveness of 
cleaning/disinfection regimes to be verified. Likewise it identifies opportunities to exclude 
redundant or unnecessary steps in the process of cleaning/disinfection and to scale down the 
bioburden sampling plan. The latter can significantly reduce costs, especially if 
microbiological testing needs to be outsourced. 
<Insert Figure 5 here> 
Installation and Operational Qualification Execution 
Integrate commissioning and qualification activities where possible 
Following good engineering practice [19], pre-validation work carried out by the engineering 
contractor or vendor, including factory acceptance testing (FAT), site acceptance testing 
(SAT) and commissioning, can be leveraged to support the IQ/OQ programme. The 
CompacT Cellbase system, for example was subjected to a separate commissioning and 
qualification (IQ/OQ) programme conducted by the vendor under the demands of their own 
Quality Systems, e.g. Good Automated Manufacturing Practice (GAMP). Under these 
circumstances, activities to integrate the vendor’s process with the facility qualification effort 
under its own validation policy require special attention. This ensures that shared 
requirements are managed by both the facility validation team and the vendor. As detailed in 
Table 1, integration of the pre-validation work into the Compact Cellbase and facility 
qualification activity yielded some important lessons with regard to maximising the 
efficiency of limited internal resources and streamlining the qualification effort. 
Page 16 of 34 
Commissioning verifies that the equipment was correctly installed, properly connected with 
site or facility services (e.g. liquid nitrogen supplies) and can be operated as specified and 
intended. Our experience shows that formal commissioning following good engineering 
practice [19] provides opportunities to leverage vendor expertise for operator training and 
transfer of best practice. For complex critical or direct impact systems in particular, the 
opportunity to test systems and components in all modes of operation is advantageous. It 
ensures that an assessment of the impact of the individual components on each of the other 
system elements is included in OQ protocols (e.g. as integrated components of the liquid 
nitrogen (LN2) systems, protocols for qualifying a controlled rate freezer (CRF) and vapour 
phase LN2 cryostore need to include an assessment of the impact of using the CRF on the 
capability of the cryostore to maintain temperature). Moreover, a pre-run of the OQ testing 
can be exploited to simplify I/OQ protocols, minimise errors or deviations in their subsequent 
execution and ultimately streamline the OQ process and its documentation. In cases where 
installed equipment has had an extended period of equipment downtime, a pre-OQ inspection 
routine (i.e. document and component verification) is advocated. This is necessary to bring 
the equipment on-line and verify that protocol requirements can be met and tested or have not 
changed due to component substitution or to design changes unknown to the validation team. 
This avoids potential IQ/OQ failures or deviations. 
Most of the temperature controlled equipment in the CTMF met their thermal OQ testing 
acceptance criteria under the relevant ISO International Standards (e.g. BS EN 60068-3-
5:2002). However in some cases equipment either needed to be modified (e.g. door seals 
replaced on freezers), their controls needed to be adjusted (e.g. set points adjusted, 
controlling probes relocated or shelves relocated for better circulation) or procedures for use 
needed to be changed in order to meet certain acceptance criteria (e.g. resulting from 
inadequate performance characteristics in terms of temperature gradients or thermal recovery). 
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These findings are likely to be all too common in facilities where the URS for temperature 
controlled equipment has not been properly verified for its intended use before being 
procured. The inappropriate installation of household fridges is a frequently encountered 
example. At best, this can lead to a situation where revalidation of the equipment is necessary 
or at worst acceptance of fridges and freezers having qualified working spaces and hence 
storage capacities well below expectation (Figure 6). 
<Insert Figure 6 here> 
Apply risk-based protocol design to reduce risk in the execution of complex aseptic 
process simulation procedures 
 
Typically aseptic process simulation or media fill studies are logistically complex and time 
consuming even when performed using less personnel-intensive aseptic processing in 
automated systems such as the CompacT Cellbase. Operational qualification for this type of 
functionally closed system is not simply a matter of testing multiple automated aseptic 
manoeuvres (e.g. dispense, aspirate, swirling, shaking, etc.). It requires a holistic 
understanding of the whole process flow and of how the process design approach interacts 
with the operator, facility, supporting equipment and operational practices. This includes the 
whole process of vaporised hydrogen peroxide (VHP) bio-decontamination, machine set up, 
reagent and controls preparation, machine loading, priming and calibrating, flask processing, 
machine unloading, flask examination and analysis. 
For instance, working with the vendor our approach was to take a systems view of the 
process and facility interfaces to identify process vulnerabilities likely to emerge under the 
operational practices of the CTMF (Figure 5). This incorporated a risk and science based 
analysis of operational and logistical conflicts as well as the manual interventions likely to 
pose the greatest risk of product contamination during the media fill (reagent/control 
preparation, loading the CompacT for example). The outcome was a media fill protocol with 
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a defined and logical sequence of process steps and a system of checkpoints to guide the 
operator and checker through the process while also providing a record of compliance 
(resembling a manufacturing batch record).    
The process simulation study, involving three consecutive automated aseptic media fills (30 
T-175 flasks/run) using a sterile microbiological growth promoting medium as a surrogate 
product, was completed successfully but not without significant issues. Equipment or utility 
malfunctions (e.g. the CompacT Cellbase, BSC, VHP equipment, HVAC systems); 
unpredictable supply chain issues, operational deficiencies or technical issues disrupted or 
caused multiple delays to the start of the programme (by over 2 months in total). Such events 
can result in costly remedial or revalidation work and/or delays to the schedule while supplies 
are replenished or key services provision rescheduled. Detailed further in Table 1, these 
experiences illustrate how aseptic media fill issues can emerge as a consequence of a 
breakdown in one or more elements of GMP and yield important lessons for protocol design 
and execution. 
<Insert Table 1 here> 
Plan for the unexpected – ‘if anything can go wrong, it will’ 
Our experience shows that small scale academic facility qualification programmes may 
expect to encounter periodic disruptions or delays of several months due to operational 
failures or unexpected events. These may be attributed to a combination of supply chain 
issues or equipment malfunctions, but more likely to recurring failures, malfunctions or 
unscheduled shutdowns of the HVAC systems that will disrupt air flow and supply quality 
e.g. pre-filter failures/blockages, air intake blockages, supply fan failure, heating/cold water 
coil failure etc.  
From the CTMF perspective for example, the most disruptive of these events resulted from 
an unforeseen occurrence in the winter of 2011 when extremely low overnight air 
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temperatures exposed weaknesses in the building infrastructure. A cascade of events that led 
to flooding and structural damage to the CBE building housing the CTMF and severely 
compromised the HVAC systems, delayed the start of the facility qualification programme by 
6 months while the physical space was recovered and environmental control re-established. 
This scenario illustrates the need to establish risk mitigation strategies and contingency plans 
as an integral part of business continuity planning and for defining facility financial liabilities 
and insurance premiums or claims.  
Actively manage the supply chain risk 
The development of a reliable supply chain should be a primary concern for small academic 
manufacturers. Technical and financial diligence of critical vendors is a part, but the scale of 
and risk to IQ/OQ activities will not usually warrant extending this oversight to the selection 
and qualification of materials/consumables suppliers until later stages of the validation plan. 
It is therefore important to establish relationships with critical component suppliers and 
service providers early in the project initiation phase. 
Locating specialised services and accredited suppliers of appropriately packaged or treated 
and often custom fabricated materials or components suitable for GMP can be a significant 
challenge, especially if the supply base is immature. Typically, pivotal aseptic media fill 
programmes can be exposed to most of this supply chain risk, as exemplified by some of the 
issues we experienced (Table 1). In some cases goods may not be available at the volumes 
required or require costly supply contracts at inappropriate scales of volume. It is also 
common for there to be only one accessible source of the material/consumable or service. 
Together, this makes the development of sufficient short-term inventories or contingency 
supply sources of critical materials difficult. It can also present logistical challenges to 
establishing windows for off-site, particularly non-local service provision e.g. for 
microbiological testing, irradiation of tubing sets and consumables etc.  
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Even with plans to reduce exposure to supply shortages and extended lead times associated 
with delivery of specialised materials or services, supply chain issues can still result in 
increased costs and delays. Experience shows that suppliers may fail to deliver goods or 
services on time through a combination of unpredictable service delivery waiting lists, 
inaccurate vendor-quoted lead times or the prioritisation practices of some suppliers and 
service providers towards low volume purchasers. Institutional processing of purchasing 
documents is another common cause for delay. 
With inadequate storage space, infrequent production runs and periods of inactivity likely to 
be a feature of small academic GMP facilities, these experiences illustrate the challenges and 
threats to developing a sustainable supply chain and purchasing cycle. If such facilities are to 
avoid exposure to supply chain risk and control high transactional costs associated with 
outsourced services, mitigation strategies will need to be incorporated into supply chain 
development, especially during the later stages of the qualification campaign. Mutual value 
propositions and service level agreements, supported by more appropriate policies for 
Institutional purchasing and tendering of GMP supplies will be a critical part of this.  
Maximise control of the HVAC systems – confront the ‘elephant in the cleanroom’ 
Part of the reality of validating an academic or hospital GMP facility is the management of 
the risks conferred by a lack of adequate control over Institutional building management or 
operational systems and the consequent exposure to unpredictable critical system failures or 
malfunctions that compromise environmental control. Engaging an external engineering 
specialist under a secondary level service agreement is one way of reinforcing oversight of 
critical HVAC systems. Our experience shows however that despite improved security and 
maintenance of critical HVAC systems, IQ/OQ activities can continue to be disrupted or put 
at risk by intermittent disturbances in the air flow and supply quality, primarily due to local 
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and site-wide operational management and HVAC control system deficiencies. Not only do 
these events interrupt pre-OQ cleaning schedules, with consequent delays to the start of OQ 
and cleaning validation activities, they also have knock on effects. For example, by 
increasing costs related to non-value added repeat cleaning programmes and the loss of 
supplies (cleaning materials/media and consumables) due to expiry or deterioration of 
packaging resulting from overextended storage in often uncontrolled environments.  
Institutional facility management functions within academic or hospital settings often lack the 
flexibility under Institutional policies and practice; have a blurring of responsibilities at the 
institutional level and poor understanding of the commercial and academic risks involved. 
Knowledge and understanding of this situation is the basis for establishing realistic 
expectations for achieving the level of control needed to maintain reliable HVAC system 
performance and facility air cleanliness. If Institutional service provision is to be prevented 
from falling short of delivering the required level of control of the HVAC systems, early 
decisions need to be made that consider (1) the feasibility of either strengthening primary 
service level agreements under existing institutional facility management arrangements or (2) 
deploying external specialist resources for PPM and control of HVAC systems under existing 
or new independent building management systems. 
Next Steps 
An operational and strategic review of the CTMF is required to revalidate the business case 
and redefine the business model framework. The organisational requirements, potential 
process development services and/or product offering need to be determined. Likewise the 
costs of sustaining business continuity and a GMP compliant facility under the scope of the 
operational transition framework, either within or outside the current Institutional 
infrastructure needs to be evaluated. This review will also need to factor in the impact of 
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recent revisions to the European guidelines for GMP [11-13] and other potential 
developments in the ATMP regulation [14,15].  
Conclusions 
As a complex, administratively-intensive, costly and time consuming undertaking, qualifying 
cell processing facilities for GMP compliance in small-scale, resource limited academic, 
hospital or small company settings can be a significant challenge, especially if they have 
limited pre-existing QA or manufacturing infrastructure [5]. This demonstrator project 
describes the process and pitfalls involved to highlight what it takes to set-up and develop an 
infrastructure for implementation of a facility qualification programme and the problems and 
constraints that the validation project team has to manage. This emphasises the additional and 
significant challenges of qualifying a novel automated processing system. Based on our 
experience, several practices are described that demonstrate potential opportunities to 
rationalise project resources and reduce or eliminate costly delays and time consuming non-
value adding qualification activities. The lessons learned and insights gained come together 
to stress the following headline propositions: (i) An effective risk based approach to product 
quality, patient safety and regulatory compliance throughout the qualification planning is 
required to ensure that critical areas are addressed and resources are not consumed by non-
value adding qualification activities; (ii) Incremental development of the facility must be 
accepted. This requires regular review, an infrastructure for continuous improvement and 
critically efficient change control mechanisms to be established as early in the project as 
possible; (iii) If an effective GMP facility is to be established, particularly in novel settings 
and immature markets, the validation team needs to extend their knowledge, understanding 
and control of supplies (both goods and services), information and financial flows across the 
entire upstream supply chain; (iv) For novel systems and settings, early and continued 
consultation with the regulator is a key component to identifying prevailing and future GMP 
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and regulatory compliance expectations and defining the scope of the qualification effort; (v) 
An understanding of the failure modes of critical or direct impact systems and utilities is 
required to specify effective testing, risk control and maintenance strategies that can improve 
their reliability and availability for qualification operations. As a postscript, although this 
occurs at an increased capital cost, if we had implemented these ‘good maintenance practices’ 
at the start of project we may have avoided many of the logistical delays we experienced due 
to system or equipment downtime associated with their diagnosis, trouble shooting, and 
repair.  
Addressing the array of challenges and constraints described in this paper was critical to 
successful facility and CompacT Cellbase qualification. It is hoped that the experiences and 
practices described will serve as a guide for other academic, hospital or small companies as 
they plan new or upgraded facilities for GMP compliant automated or manual manufacture of 
autologous cell-based therapies. 
Executive summary 
Project Initiation 
• Unpredictable resources in non-commercial settings define the need for progressive and 
integrated approaches to both facility qualification and business strategy development. 
• Establish a project team with experience, knowledge and expertise in specialised fields of 
automated cell culture, quality assurance, GMP manufacturing and regulatory compliance  
• Apply quality management tools to build a high level mutual understanding of the project scope 
and workflow, agree its boundaries and the expectations of customers and suppliers. 
Project Planning 
• Implement a modular validation approach to reduce project complexity and establish priorities. 
• Complete a formal regulatory and GMP requirements analysis to identify gaps or areas and where 
clarification of the regulatory compliance expectation is required.  
• Establish early consultation with the MHRA and an interface with the Institutional facility 
management function  
Installation and Operational Qualification Readiness 
• Employ a rigorous structured design review of the facility and a remedial plan to address 
compliance and quality gaps prior to the execution of IQ and OQ activities.  
• Implement a risk-based contamination control strategy to maximise facility environmental control 
and operating efficiencies before OQ of critical or direct impact equipment.  
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• Perform a sequenced IQ of each room in the facility so that equipment maintenance/calibration 
activities, implementation of risk controls (e.g. cleaning/disinfection, dress code and training 
regimes) and supply chain activities can be prioritised.  
Installation and Operational Qualification Execution 
• Use good engineering practice to leverage pre-validation work and vendor expertise to support the 
IQ/OQ programme.  
• Develop risk-based challenge tests early in the project to evaluate the potential risks of 
contamination and cross-contamination in the automated autologous product processing area. 
• Design and develop risk-based protocols for the execution of complex aseptic process simulation 
procedures based on learning from factory acceptance testing and trial runs.  
• Actively manage vulnerabilities and exposure to upstream supply chain risks.  
• Maximise control of the HVAC systems and their AHU units under existing institutional facility 
management arrangements or under new independent building management systems. 
 
Future perspective 
Building on the science and risk based International Conference on Harmonisation (ICH) 
guidelines, specifically ICH Q8, Q9, Q10 and Q11, new concepts and approaches to 
validation and change control are being promoted through U.S FDA and EMA initiatives and 
the work of ISPE and others [11,22]. New European process validation guidelines, adaptation 
of Annex 2 to ATMPs and impending revisions to Annex 15 of the European guidelines for 
GMP [11-13] put forward more progressive and graded validation pathways that will afford 
manufacturers new possibilities for manufacturing efficiency and flexibility.  
Merging science-based risk management with an integrated Quality Systems approach will 
move validation away from traditional system-based approaches [19], placing greater reliance 
on process knowledge, understanding and control to assure product safety and efficacy. 
Experience from the pharmaceutical/biopharmaceutical industry suggests that the adoption of 
these approaches by the cell therapy industry will rely on advances in the state of current 
technology. Step changes in real time process monitoring capability and development of 
stable surrogate or reference cell lines and other industry standards, as a way of addressing 
Quality by Design like manufacturing design practice and continuous process verification 
approaches will be an integral part of this. Likewise advances in closed or functionally closed 
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automated processing technology for cell manipulation, whether in the factory or hospital 
setting, will be a critical step. By reducing operator variation and eliminating the external 
environment, these systems will likely make validation of facility infrastructure and the 
manufacturing process intrinsically more straightforward and cost effective, besides being 
more amenable to change control and the demonstration of comparability [23].   
The potential progress in some of these areas has been recognised in a recent report published 
by the European Commission in April this year following public consultation on the 
application of the Regulation (EC) No 1394/2007 on ATMPs [14,15]. Significantly, this 
report raises new possibilities for academic and other ATMP developers, not least with the 
recognition that the specific characteristics of autologous products and their manufacturing 
processes deserve specific consideration.  
If the regulatory framework continues to adapt to rapid scientific progress and technological 
advances in cell-based therapy manufacturing, as an industry we will be able to derive and 
implement better and more effective ways of qualifying our facilities, equipment and 
automated manufacturing systems. Coupled with potentially far reaching changes to the 
ATMP regulation [15], this will ensure that our facilities and manufacturing systems are 
delivered fit for purpose and capable of supporting the reproducible manufacture of quality 
cell-based autologous therapy products across multiple manufacturing sites while controlling 
risk to patient safety. 
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Figure Legends 
 
Figure 1. Layout of the primary elements of the Cell Therapy Manufacturing Facility.  
Occupying a total space of about 70 m2, the facility comprises a manual operations room (equipped 
with fridge, freezer, incubator and a Biological Safety Cabinet (BSC)) and a machine room for 
automated aseptic manufacture (equipped with the Compact Cellbase and a fridge). Both rooms are 
classified as Grade B (shaded green), as defined by Annex 1 of the EU guidelines for GMP [8], and 
meet the physical containment level 2 requirements. The BSC and CompacT Cellbase provide Grade 
A classified environments (shaded red). The facility also includes a Grade C (shaded yellow) 
cryopreservation room (equipped with a controlled rate freezer and a vapour phase liquid nitrogen 
(LN2) cryostorage unit supplied via insulated vacuum lines from two 240L LN2 supply tanks located 
outside the controlled area); unclassified (shaded white) material storage areas and a pass through 
room (equipped with a freezer and a controlled temperature storage area (4°C)). In addition there are 
off-facility areas for writing-up, bulk storage of supplies and documents. Rooms are isolated from 
each other by sealed walls with no connecting doors. The facility has controlled access for entrance 
and enforces unidirectional traffic flow patterns for personnel, materials, products, and waste via 
transfer hatches and two change/gowning rooms (Grade B and Grade C). The HVAC systems and 
their AHUs are located in the plant room above the facility. The facility environment is continuously 
monitored via a local Facility Management System, including non-viable particle counts (0.5 and 5.0 
µm) in grade B rooms and in Grade A environments, pressure differentials between rooms within the 
facility, humidity and temperature in the automated processing room, as well as temperature and CO2 
of storage units. 
 
Figure 2. Photograph of the Compact Cellbase system (TAP Biosystems).  
Located in the Grade B automated cell culture laboratory within the Cell Therapy Manufacturing 
Facility, the Compact CellBase is an automated system designed and tested to support the 
development and manufacture of autologous cell therapy products. The CompacT CellBase automates 
the maintenance and expansion of cells in T-175 flasks from multiple patients within a Grade A 
classified environment [8] behind a restricted access barrier system under negative pressure, 
protecting the operator and ensuring aseptic processing of the products. Design elements include; 10 
pumps for programmable media and reagent dispense, automated temperature and CO2 controlled 
incubator for 90 T-175 flasks and automated cell counting and viability measurement.  
 
Figure 3. Schematic of the modular validation strategy.  
Shows primary document development for the separate related qualification programmes under 
independent validation plans (VP) defined in the Master Validation Plan (MVP). Grey highlights 
indicate the scope of facility qualification activities addressed in this paper. Glossary: DQ = design 
qualification; IQ = installation qualification; OQ = operational qualification; PQ = performance 
qualification; CV = cleaning validation; CSV = computer system validation; ASV = analytical system 
validation; AMV = analytical method validation. 
 
Figure 4: Cell Therapy Manufacturing Facility Operational Status Levels.  
Key: Decommissioned level (out of service); Level 4 - Under validation (some controls will be in 
place whilst the facility is validated but no product will be present and therefore the risk is minimal); 
Level 3 - Hibernation (validated facility, no product or active materials present, minimal entry and 
exit); Level 2 - Operational (validated facility for storage and handling of product (in secondary 
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packaging) and active materials); Level 1 - Aseptic manufacture (validated facility for cell culture 
operations, product processing, product handling in primary and secondary packaging). 
Figure 5. System diagram of Cell Therapy Manufacturing Facility interfaces. Factors and risk 
nodes influencing outcomes of automated aseptic processing and levels of contamination. 
Figure 6. Schematic of temperature sensor positions for Operational Qualification of Freezer. 
Thermal profile showing mean temperature (°C) at each probe position and for the remote Facility 
Management System (FMS) probe (-25.7°C). In general the temperature gradient shows a significant 
increase in the top half of the freezer particularly at the front compared to the bottom half, with mean 
temperatures outside the specification (-20°C to -30°C). Sensors positioned according BS (EN 60068-
3-5:2002). Corner sensors secured approximately 50 mm in from chamber walls. 
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Table 1. Qualification of the CompacT Cellbase system: Major lessons learned from the 
perspective of the CTMF validation team 
Parameter Summary of Lessons Learned 
Regulatory 
Requirements: 
Analysis  
Conducting a regulatory requirement analysis early in the project initiation 
phase was critical for identifying areas or gaps where clarification on how the 
existing regulations apply to the qualification of the CompacT Cellbase system. 
Consultation with 
the UK Regulator 
(MHRA) 
Early consultation with the MHRA was crucial to identifying critical CompacT 
Cellbase system design features likely to come under the highest regulatory 
scrutiny i.e. its air handling systems, its ‘cleanability’ and its integration with 
the facility cleanroom and connected utilities.  
As a critical component of the system Design Qualification (DQ), complex and 
extensive risk-based challenge tests (Box 1) need to be developed to evaluate 
the potential risks of contamination and cross-contamination in the automated 
processing area.  
Commissioning 
and Qualification 
Integration 
Following good engineering practice [19], coordinating and integrating the 
factory acceptance testing (FAT), pre-delivery inspection (PDI), site acceptance 
testing (SAT) and commissioning of the system with the DQ and design review 
of the facility can realise cost and time savings in the qualification programme.  
‘Hands on’ involvement of members of the CTMF validation team in the 
inspection and testing of the system during FAT and PDI at the vendors’ site 
was critical. Input from those with deep domain knowledge and experience in 
manual aseptic culture processes and from a representative from the MHRA 
was equally critical.  
Involving this team in the pre-validation work allowed a quicker and more 
efficient resolution of minor issues with the equipment and of compliance gaps 
in the functional and physical arrangement of the facility. Delays that would 
have resulted from discovering problems with the equipment or its installation 
after on-site delivery were avoided. By identifying critical operational criteria 
that require testing during the FAT/SAT the duration of the OQ was 
significantly shortened. 
Operational 
Qualification (OQ) 
Readiness 
Maximising facility environmental control and process critical equipment / 
system operating efficiencies before the OQ of the CompacT Cellbase was 
critical for successful execution. This included: 
 Implementation of risk control mechanisms (cleaning/disinfection, dress 
code or training regimes) to address the potential risk of contamination as 
part of a facility contamination control plan and the OQ protocol.  
 Prioritisation of the sequence of critical facility, equipment and utilities 
SAT and OQ execution.    
 Surveillance of continuous environmental and facility infrastructure data to 
provide early warnings of facility/equipment operational inefficiencies or 
environmental disturbances (i.e. that may result in increased particle 
counts). This allows early recognition of the relevant risk and mitigation 
actions to be initiated before the OQ activity can be disrupted or 
compromised.   
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Table 1. Continued… 
Parameter Summary of Lessons Learned 
Aseptic Process 
Simulation  
Aseptic connections and manual manipulations during the set-up of the machine 
by the operator are vulnerable to operator error and integrity failures in the 
connector-tube line assemblies (e.g. media bag to machine). This can result in 
leakages and potential exposure of media to contamination. Novel protocol 
design approaches therefore need to involve a risk based evaluation of how 
dynamic operational, ergonomic and human factors can interact. It is of note 
that these interactions are often neglected by many suppliers/vendors.  
The set-up and preparation of the CompacT Cellbase involves multiple manual 
interventions. These include the aseptic loading, location, placement, 
attachment and removal of equipment components and labware, such as waste 
trays, tubing, indicator strips, pipette canisters, media bags, flasks and reagents 
etc., Just as all these elements need to be tested during the FAT, extended 
reliability tests should also be a key component in testing the multiple 
automated manoeuvres involved.   
Likewise, early learning or trial periods provide an opportunity to uncover and 
correct unforeseen critical risk factors and process vulnerabilities, operational 
deficiencies and logistical conflicts. 
Operator training and proficiency testing of aseptic technique and measurement 
capabilities (e.g. visual detection of turbid units) is advocated to reduce novelty 
in the procedure, help drive error rates down and reduce the chance that 
deviation will occur. 
Supply Chain 
Management 
As a logistically complex and extended (28 days) task, aseptic process 
qualification is operationally difficult to schedule and is vulnerable to upstream 
supply risks.  
In immature markets, small-scale facilities using novel automated systems 
should not underestimate the lead times and costs involved in procuring 
specialised services (e.g. for VHP decontamination, irradiation of consumables, 
bioburden testing) and locating accredited suppliers of appropriately packaged 
or treated and custom fabricated materials or components suitable for GMP 
(e.g. pre-filled culture media bags).  
As a small scale academic facility, it may not be possible to establish mutual 
value propositions or primary service level agreements with vendors. It is 
therefore critical to establish informal relationships with suppliers of critical 
goods or services early in the project, bearing in mind that the provision of 
certain customised supplies e.g. appropriately packaged ‘triple bagged’ 
consumable components such as flasks and pipettes, may require the supplier to 
change their manufacturing processes and/or issue new products codes. 
Likewise practices for institutional purchasing and tendering practices of these 
specialist goods and services need to be developed if further delays are to be 
avoided. 
 
